Skip to main content
. 2023 Feb 7;18(2):e0281402. doi: 10.1371/journal.pone.0281402

Table 2. Key parameters input in the model.

Variable Value Range Distribution Reference
Transition probabilities
Anlotinib group
Progression from stable state 0.039 0.031 to 0.047 Beta [9]
Death from stable state 0.022 0.018 to 0.026 Beta [9]
Mortality after progression 0.050 0.040 to 0.061 Beta [9]
Sunitinib group
Progression from stable state 0.041 0.033 to 0.049 Beta [9]
Death from stable state 0.022 0.018 to 0.026 Beta [9]
Mortality after progression 0.049 0.039 to 0.059 Beta [9]
Utilities
Stable state 0.730 0.584 to 0.876 Beta [1517]
Progressive state 0.660 0.528 to 0.792 Beta [1517]
Disutility due to AEs (grade ≥3) 0.157 0.126 to 0.188 Beta [1517]
Costs per cycle, $
Anlotinib 864.76 691.81 to 1037.71 Gamma Local charge
Sunitinib 1830.48 1464.38 to 2196.58 Gamma Local charge
Societal costs 54.58 43.66 to 65.50 Gamma [14]
Tests 248.96 199.17 to 298.75 Gamma Local charge
Outpatient fees 6.32 5.06 to 7.58 Gamma Local charge
Grade ≥3AEs in anlotinib group 23.76 19.01 to 28.51 Gamma Expert Opinion
Grade ≥3AEs in sunitinib group 265.44 212.35 to 318.53 Gamma Expert Opinion
Costs for progressive state 4535.08 3628.06 to 5442.10 Gamma [15]